Patent application number | Description | Published |
20080267953 | Anti-perp recombinant antibody - An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene. | 10-30-2008 |
20090202556 | ANTI-CLAUDIN-4 ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as “CLDN4”) gene or a polypeptide encoded by a Claudin-3 (hereinafter referred to as “CLDN3”) gene, or a method for using the same. Accordingly, the present invention provides a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of an extracellular region of CLDN4 and binds to the extracellular region; a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of both of extracellular regions of CLDN3 and CLDN4 and binds to the extracellular regions; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtained by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by CLDN4 gene and/or CLDN3 gene using the antibody or the antibody fragment. | 08-13-2009 |
20100092997 | Method of Enhancing of Binding Activity of Antibody Composition to FcGamma Receptor IIIa - A method for enhancing a binding activity of an antibody composition to Fcγ receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcγ receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same. | 04-15-2010 |
20100143388 | Antibody Composition-Producing Cell - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 06-10-2010 |
20100184958 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR - Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF. | 07-22-2010 |
20100196371 | METHOD OF MODULATING THE ACTIVITY OF FUNCTIONAL IMMUNE MOLECULES - The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity. | 08-05-2010 |
20100221178 | Method for Treating the TH2-Mediated Disease - A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer. | 09-02-2010 |
20110034673 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR - Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF. | 02-10-2011 |
20110052595 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR - Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF. | 03-03-2011 |
20110059524 | HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF - A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient. | 03-10-2011 |
20110250643 | ANTIBODY COMPOSITION-PRODUCING CELL - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 10-13-2011 |
20120177643 | HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF - A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient. | 07-12-2012 |
20130337505 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR - Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a method for producing a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF. | 12-19-2013 |
20140186349 | HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF - A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient. | 07-03-2014 |
20140234300 | METHOD OF MODULATING THE ACTIVITY OF FUNCTIONAL IMMUNE MOLECULES - The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity. | 08-21-2014 |